{"id":2322,"date":"2014-10-22T18:00:06","date_gmt":"2014-10-22T16:00:06","guid":{"rendered":"http:\/\/news.embl.de\/?p=2322"},"modified":"2024-11-14T16:31:21","modified_gmt":"2024-11-14T15:31:21","slug":"1410_autoimmune_disorders","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/","title":{"rendered":"Protecting us from our cells"},"content":{"rendered":"\n<p>Our immune system defends us from harmful bacteria and viruses, but, if left unchecked, the cells that destroy those invaders can turn on the body itself, causing auto-immune diseases like type-1 diabetes or multiple sclerosis. A molecule called insulin-like growth factor-1 (IGF-1) boosts the body\u2019s natural defence against this \u2018friendly fire\u2019, scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, have found. The findings, published today in <em>EMBO Molecular Medicine<\/em>, are especially exciting because IGF-1 is already approved for use in patients, which could speed up the move to clinical trials for treating auto-immune diseases.<\/p>\n\n\n\n<p>\u201cTo me what was really striking was the survival rate for multiple sclerosis,\u201d says <a title=\"Daniel Bilbao\" href=\"http:\/\/www.embl.it\/research\/unit\/avner\/members\/index.php?s_personId=CP-60002242\" target=\"_blank\" rel=\"noopener noreferrer\">Daniel Bilbao<\/a>, who conducted the research with Nadia Rosenthal\u2019s lab at EMBL, \u201cwe went from less than 50% survival in untreated animals to over 80% survival in animals that received IGF-1.\u201d<\/p>\n\n\n\n<p>In patients with auto-immune diseases, a group of cells called pro-inflammatory T-effector cells become sensitized to specific cells in the body, identifying them as foreign and attacking them as if they were invading bacteria. If this misdirected attack targets the insulin-producing cells in the pancreas, the result is diabetes; if it affects myelin-sheathed cells in the central nervous system, the person suffers from multiple sclerosis. These attacks on the body\u2019s own cells go unchecked due to the failing of another type of immune cell: T-regulatory (T-reg) cells, which, as their name implies, control T-effector cells, shutting them down when they are not needed.<\/p>\n\n\n\n<blockquote class=\"vf-blockquote\"><p>My hope and goal is to now see this applied to humans<\/p><\/blockquote>\n\n\n\n<p>Working with then PhD student Luisa Luciani, Bilbao and Rosenthal found that, if mice with conditions that mimic type-1 diabetes and multiple sclerosis received IGF-1, they started producing more T-reg cells where they were needed \u2013 the pancreas and the central nervous system, respectively \u2013 and the disease was suppressed. The scientists went on to test IGF-1\u2019s effects on T-reg cells taken from both mice and humans, confirming that IGF-1 acts directly on T-reg cells \u2013 rather than indirectly by affecting some other factor that induces T-reg cells to multiply.<\/p>\n\n\n\n<p>In a separate study published earlier this year, Bilbao and Rosenthal had found that IGF-1 has the same effect on another condition in which the immune system goes awry. They found that allergic contact dermatitis, an inflammatory skin disease thought to affect as many as one in five Europeans, is also suppressed in mice by treating them with IGF-1.<\/p>\n\n\n\n<p>\u201cThese studies have real clinical significance, because IGF-1 is already an approved therapeutic, which has been tested in many different settings, so it will be much easier to start clinical trials for IGF-1 in auto-immune and inflammatory diseases than it would if we were proposing a new, untested drug,\u2019 says Nadia Rosenthal, former Head of EMBL Monterotondo, and currently at Imperial College London, UK, and Monash University, Australia, where she is Scientific Head of EMBL Australia.<\/p>\n\n\n\n<p>\u201cMy hope and goal is to now see this applied to humans, but \u2013 as with everything \u2013 that will depend on funding,\u201d Bilbao adds.<\/p>\n\n\n\n<p>Rosenthal is planning to further explore the role of IGF-1 in inflammation and regeneration, and its potential for treating conditions such as muscular atrophy, fibrosis or heart disease.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Growth factor IGF-1 boosts natural defence against type-1 diabetes and multiple sclerosis<\/p>\n","protected":false},"author":8,"featured_media":2334,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2,17591],"tags":[32,74,1748,514],"embl_taxonomy":[],"class_list":["post-2322","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science","category-science-technology","tag-health","tag-monterotondo","tag-press-release","tag-rome"],"acf":{"article_intro":"<p>A molecule called insulin-like growth factor-1 (IGF-1) boosts the body\u2019s natural defence auto-immune diseases such as type-1 diabetes and multiple sclerosis, scientists at EMBL Monterotondo have found. The findings are especially exciting because IGF-1 is already approved for use in patients, which could speed up the move to clinical trials for treating auto-immune diseases.<\/p>\n","related_links":[{"link_description":"This article was first published as an EMBL Press Release","link_url":"www.embl.org\/press\/2014\/141022_Monterotondo"},{"link_description":"EMBL Australia","link_url":"http:\/\/www.emblaustralia.org\/"},{"link_description":"Nadia Rosenthal, Imperial College London","link_url":"http:\/\/www.imperial.ac.uk\/AP\/faces\/pages\/read\/Home.jsp?person=n.rosenthal"}],"article_sources":[{"source_description":"<p>Bilbao\u00a0<em>et al<\/em>.\u00a0<i>EMBO Molecular Medicine<\/i>,<i>\u00a0<\/i>22 October 2014. DOI: 10.15252\/emmm.201303376<\/p>\n","source_link_url":"http:\/\/dx.doi.org\/10.15252\/emmm.201303376"}],"vf_locked":false,"featured":false,"color":"#007B53","show_featured_image":false,"in_this_article":false,"youtube_url":"","mp4_url":"","video_caption":"","translations":false,"press_contact":"EMBL Generic"},"embl_taxonomy_terms":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Protecting us from our cells | EMBL<\/title>\n<meta name=\"description\" content=\"Growth factor IGF-1 boosts natural defence against autoimmune disorders like type-1 diabetes and multiple sclerosis\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Protecting us from our cells | EMBL\" \/>\n<meta property=\"og:description\" content=\"Growth factor IGF-1 boosts natural defence against autoimmune disorders like type-1 diabetes and multiple sclerosis\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-22T16:00:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-14T15:31:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2014\/10\/pr22oct14mr_etc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"425\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sonia Furtado Neves\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Aur_ora\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sonia Furtado Neves\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/\"},\"author\":{\"name\":\"Sonia Furtado Neves\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/d926199a955624b44dda296f396c5e68\"},\"headline\":\"Protecting us from our cells\",\"datePublished\":\"2014-10-22T16:00:06+00:00\",\"dateModified\":\"2024-11-14T15:31:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/\"},\"wordCount\":537,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2014\/10\/pr22oct14mr_etc.jpg\",\"keywords\":[\"health\",\"monterotondo\",\"press release\",\"rome\"],\"articleSection\":[\"Science\",\"Science &amp; Technology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/\",\"url\":\"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/\",\"name\":\"Protecting us from our cells | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2014\/10\/pr22oct14mr_etc.jpg\",\"datePublished\":\"2014-10-22T16:00:06+00:00\",\"dateModified\":\"2024-11-14T15:31:21+00:00\",\"description\":\"Growth factor IGF-1 boosts natural defence against autoimmune disorders like type-1 diabetes and multiple sclerosis\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2014\/10\/pr22oct14mr_etc.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2014\/10\/pr22oct14mr_etc.jpg\",\"width\":620,\"height\":425,\"caption\":\"Treatment with IGF-1 (middle) brings the pancreas of mice suffering from diabetes (left) close to normal (right). IMAGE: EMBL\/D.BILBAO\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/d926199a955624b44dda296f396c5e68\",\"name\":\"Sonia Furtado Neves\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/85ae4046e9b9b00d1fbd909d6541dc5522ea35db24faaf4b2a5ebcc56dd4846f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/85ae4046e9b9b00d1fbd909d6541dc5522ea35db24faaf4b2a5ebcc56dd4846f?s=96&d=mm&r=g\",\"caption\":\"Sonia Furtado Neves\"},\"description\":\"Sonia Furtado Neves is EMBL's Core Content Manager and Press Officer. The world never ceases to stun her, and she loves sharing that awe, wonder and amazement.\",\"sameAs\":[\"https:\/\/x.com\/Aur_ora\"],\"url\":\"https:\/\/www.embl.org\/news\/author\/sonia\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Protecting us from our cells | EMBL","description":"Growth factor IGF-1 boosts natural defence against autoimmune disorders like type-1 diabetes and multiple sclerosis","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/","og_locale":"en_US","og_type":"article","og_title":"Protecting us from our cells | EMBL","og_description":"Growth factor IGF-1 boosts natural defence against autoimmune disorders like type-1 diabetes and multiple sclerosis","og_url":"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2014-10-22T16:00:06+00:00","article_modified_time":"2024-11-14T15:31:21+00:00","og_image":[{"width":620,"height":425,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2014\/10\/pr22oct14mr_etc.jpg","type":"image\/jpeg"}],"author":"Sonia Furtado Neves","twitter_card":"summary_large_image","twitter_creator":"@Aur_ora","twitter_site":"@embl","twitter_misc":{"Written by":"Sonia Furtado Neves","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/"},"author":{"name":"Sonia Furtado Neves","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/d926199a955624b44dda296f396c5e68"},"headline":"Protecting us from our cells","datePublished":"2014-10-22T16:00:06+00:00","dateModified":"2024-11-14T15:31:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/"},"wordCount":537,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2014\/10\/pr22oct14mr_etc.jpg","keywords":["health","monterotondo","press release","rome"],"articleSection":["Science","Science &amp; Technology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/","url":"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/","name":"Protecting us from our cells | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2014\/10\/pr22oct14mr_etc.jpg","datePublished":"2014-10-22T16:00:06+00:00","dateModified":"2024-11-14T15:31:21+00:00","description":"Growth factor IGF-1 boosts natural defence against autoimmune disorders like type-1 diabetes and multiple sclerosis","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/science\/1410_autoimmune_disorders\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2014\/10\/pr22oct14mr_etc.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2014\/10\/pr22oct14mr_etc.jpg","width":620,"height":425,"caption":"Treatment with IGF-1 (middle) brings the pancreas of mice suffering from diabetes (left) close to normal (right). IMAGE: EMBL\/D.BILBAO"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/d926199a955624b44dda296f396c5e68","name":"Sonia Furtado Neves","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/85ae4046e9b9b00d1fbd909d6541dc5522ea35db24faaf4b2a5ebcc56dd4846f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/85ae4046e9b9b00d1fbd909d6541dc5522ea35db24faaf4b2a5ebcc56dd4846f?s=96&d=mm&r=g","caption":"Sonia Furtado Neves"},"description":"Sonia Furtado Neves is EMBL's Core Content Manager and Press Officer. The world never ceases to stun her, and she loves sharing that awe, wonder and amazement.","sameAs":["https:\/\/x.com\/Aur_ora"],"url":"https:\/\/www.embl.org\/news\/author\/sonia\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2014\/10\/pr22oct14mr_etc.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2014\/10\/pr22oct14mr_etc.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/2322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=2322"}],"version-history":[{"count":6,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/2322\/revisions"}],"predecessor-version":[{"id":24192,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/2322\/revisions\/24192"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/2334"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=2322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=2322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=2322"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=2322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}